nonmyeloablative allogeneic hematopoietic stem cell transplantation in the treatment of pancreatic cancer

Conditions: Pancreatic Cancer Stage III; Pancreatic Cancer Stage IV

Summary: to evaluate the safety and efficacy of non-myeloablative hematopoietic stem cell transplantation in the treatment of pancreatic cancer.

allogeneic hematopoietic stem cell transplantation has been successfully used for the treatment of hematopoietic malignancy. in recent years, non-myeloablative hematopoietic stem cell transplantation (nst) has been introduced to treat solid tumors due to the graft-versus tumor effect. in this study, the investigators try to evaluate the safety and efficacy of nst in the treatment of unresectable pancreatic cancer patients.

Eligibility criteria:
inclusion criteria: * pet-ct/eus-fna cytologically confirmed stage iii -ⅳ of pancreatic cancer * between 18 and 80 years old * karnofsky performance status (kps) ≥ 70%，guaranteed treatment for 3 months * normal functions of heart, lung and kidney * adequate hematological profile： hemoglobin ≥ 9.0 g/dl、 absolute granulocyte count ≥ 1,500/mm\^3 、platelet count ≥ 100,000/mm\^3， start the treatment within 14 days after these results meet the requirements * a life expectancy \> 3 months * informed consent signed * hla-haplotype-matched immediate family health donors who have been confirmed by laboratory hla genotypes * interval the last anti-tumor treatment for more than 3 months exclusion criteria: * highly allergic or people with severe allergies * brain metastasis or primary central nervous system malignancy * suffer from clinical illnesses that affect clinical trials, including but not limited to： uncontrollable diabetes；active infectious disease or uncontrollable infection; acute and chronic liver disease; confirmation of hiv infection; uncontrollable hypertension, symptomatic congestive heart-failure, unstable angina pectoris, and myocardial infarction, uncontrollable arrhythmia over the last 6 months. * combined heart, lung, kidney and other vital organs dysfunction * a serious coagulation dysfunction, a clear history of other tumors * pregnant and lactating women * mental illness, affecting the compliance of clinical trials * the patient will participate in other trials within 10 days prior to the trial or while participating in other tests * patients underwent weight loss by 10% and above within 6 weeks before the start of the trial * neutrophils\<500mm\^3 or platelet count\<50,000/mm\^3 * need to drive and manipulate the machine during the trial donor's inclusion criteria: * first-degree relatives of patients * age\<55 years old * normal functions of heart, lung and kidney * adequate hematological profile： hemoglobin ≥ 9.0 g/dl、 absolute granulocyte count ≥ 1,500/mm\^3 、platelet count ≥ 100,000/mm\^3、wbc≥ 3000/mm\^3， start collecting stem cells within 14 days after these results meet the requirements * informed consent signed donor's exclusion criteria: * highly allergic or people with severe allergies * the person who have history of atherosclerosis, venous thrombosis or autoimmune disease * a serious coagulation dysfunction, a clear history of other tumors * infectious disease or carriers * pregnant and lactating women * mental illness, affecting the compliance of clinical trials * wbc\<4000/mm\^3、plt\<70\*10\^9/l